18 May 2013
Keywords: Cellceutix, Kevetrin, Leukemia, p53, IND filing
Article | 08 March 2011
Massachusetts, USA-based Cellceutix (OTCQB: CTIX) says that its flagship cancer compound, Kevetrin, has demonstrated potent anti-tumor activity in the treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 March 2011
17 May 2013
© 2013 thepharmaletter.com